SAGITTA contains imatinib mesylate, a second generation tyrosine kinase inhibitor, as hard capsules, is available in the following dosage forms: - 100mg capsules, packs of 60 - 400mg capsules, packs of 30
SAGITTA is indicated for the treatment of Philadelphia chromosome
(bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia
chromosome positive acute lymphoblasti
© Copyright 2024. All Rights Reserved.